BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia

Victoria Del Gaizo Moore, Krysta Schlis, Stephen E. Sallan, Scott A. Armstrong, Anthony Letai

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.

Original languageEnglish (US)
Pages (from-to)2300-2309
Number of pages10
JournalBlood
Volume111
Issue number4
DOIs
StatePublished - Feb 15 2008
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cells
Apoptosis
Cell Line
Proteins
Neoplasms
Signal transduction
Genomic Instability
Oncogenes
2-(4'-diethylaminophenyl)benzothiazole
ABT-737
Assays
Signal Transduction
Intercellular Signaling Peptides and Proteins
Chemical activation
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

Del Gaizo Moore, V., Schlis, K., Sallan, S. E., Armstrong, S. A., & Letai, A. (2008). BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood, 111(4), 2300-2309. https://doi.org/10.1182/blood-2007-06-098012

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. / Del Gaizo Moore, Victoria; Schlis, Krysta; Sallan, Stephen E.; Armstrong, Scott A.; Letai, Anthony.

In: Blood, Vol. 111, No. 4, 15.02.2008, p. 2300-2309.

Research output: Contribution to journalArticle

Del Gaizo Moore, V, Schlis, K, Sallan, SE, Armstrong, SA & Letai, A 2008, 'BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia', Blood, vol. 111, no. 4, pp. 2300-2309. https://doi.org/10.1182/blood-2007-06-098012
Del Gaizo Moore, Victoria ; Schlis, Krysta ; Sallan, Stephen E. ; Armstrong, Scott A. ; Letai, Anthony. / BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. In: Blood. 2008 ; Vol. 111, No. 4. pp. 2300-2309.
@article{589faaf3e16d478cbbb902f05ebe8377,
title = "BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia",
abstract = "Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.",
author = "{Del Gaizo Moore}, Victoria and Krysta Schlis and Sallan, {Stephen E.} and Armstrong, {Scott A.} and Anthony Letai",
year = "2008",
month = "2",
day = "15",
doi = "10.1182/blood-2007-06-098012",
language = "English (US)",
volume = "111",
pages = "2300--2309",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia

AU - Del Gaizo Moore, Victoria

AU - Schlis, Krysta

AU - Sallan, Stephen E.

AU - Armstrong, Scott A.

AU - Letai, Anthony

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.

AB - Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=41349123507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349123507&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-06-098012

DO - 10.1182/blood-2007-06-098012

M3 - Article

VL - 111

SP - 2300

EP - 2309

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -